Cheryl Thompson
Family Medicine · Vista, CANPI 1548429863
Payments from drug & device makers
What this record shows
16 manufacturers reported payments, led by Eli Lilly at 58.0% of the total. Reporting peaked in 2023 at $1,121 and has fallen 96.0% since, to $45 in 2025.
Across 40 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$966
- Novo Nordisk$110
- Gilead$92
- Johnson & Johnson$86
- Astellas Pharma US Inc$75
- Pfizer$60
- plus $276 from 10 others
Across 17 payments — averaging $42,628 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$725K
What the payments were for
- Travel & lodging$96658%
- Food & beverage$69842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 3 | $966 |
| Novo Nordisk | 6 | $110 |
| Gilead | 2 | $92 |
| Johnson & Johnson | 6 | $86 |
| Astellas Pharma US Inc | 5 | $75 |
| Pfizer | 3 | $60 |
| Cranial Technologies, Inc | 3 | $48 |
| Viiv Healthcare Company | 2 | $39 |
| AbbVie | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $35 |
| GSK | 1 | $25 |
| Mylan Specialty L.p. | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$1,665 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $86,448 |
| OzempicSemaglutide | 49 | $43,579 |
| JanuviaSitagliptin Phosphate | 29 | $29,361 |
| TradjentaLinagliptin | 11 | $12,420 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $12,086 |
| VascepaIcosapent Ethyl | 14 | $7,994 |
| MyrbetriqMirabegron | 13 | $7,857 |
| Repatha SyringeEvolocumab | 11 | $5,726 |
| Sucralfate | 28 | $4,212 |
| Insulin Aspart FlexpenInsulin Aspart | 16 | $3,384 |
| Insulin Aspart Prot Mix 70-30Insulin Aspart Prot/Insuln Asp | 12 | $3,059 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $2,644 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,547 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $2,109 |
| Omega-3 Acid Ethyl Esters | 28 | $1,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $110 | $55,66460 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $7,85713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Vista
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.